查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197414

生命科學工具市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Life Science Tools Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

生命科學工具市場預計在預測期內的複合年增長率為 7.5%。

在全球範圍內，COVID-19 大流行對生命科學工具市場的增長產生了積極影響，導致診斷技術快速發展，監管審批迅速，每個國家的分銷量都有所增加。 不同的診斷程序對於傳染病的檢測始終是必不可少的。 目前正在進行幾種分子和免疫測定來檢測 COVID-19。 然而，在大流行之後，生命科學行業正在積極研究如何為全球大流行的意外負擔做準備。 例如，2022 年 9 月，世衛組織發布了負責任地使用生命科學工具的指導框架。 該框架將指導領導者降低風險並安全地管理具有明顯好處但可能被濫用以傷害人類、其他動物、農業和環境以及其他相關方的雙重用途研究。 因此，隨著對生命科學的日益關注，預計未來幾年所研究的市場將顯著增長。

基因組技術在全球範圍內越來越多地被用於了解各種疾病，並有助於開發新的診斷測試和程序，從而推動市場的增長。 例如，2022 年 9 月，Becton, Dickinson, and Company (BD) 和 CerTest Biotec 開始在美國和全球市場商業分銷一種新的猴痘病毒分子聚合□鏈反應 (PCR) 檢測方法。 該公司表示，這種 PCR 檢測僅用於研究目的。 隨著此類新試劑的推出，市場有望在預測期內實現強勁增長。

此外，與測序技術、色譜法、質譜法等相關的技術進步增加了醫院、實驗室和診斷實驗室對這些工具的採用。 根據世衛組織 2021 年情況說明書，680,000 人死於與艾滋病毒相關的原因，150 萬人感染了艾滋病毒。 因此，高患者數量將推動對治療的需求，進一步增加生命科學工具的使用，以識別、診斷和監測某些傳染病的進展。

此外，對各種傳染病診斷測試的需求不斷增長，將刺激用於診斷目標人群的生命科學工具的發展，並在預測期內推動整個市場的增長。看來。

生命科學工具的市場趨勢

分離技術生命科學工具預計在預測期內實現健康增長

分離技術領域的主要驅動力包括增加對藥物研發的投資以及生命科學行業對色譜技術的更多采用。

在全球範圍內，COVID-19 的爆發對生命科學設備市場產生了積極影響。 由於 COVID-19 爆發引起的疾病增加，後續的研發活動有所增加。 增加對藥物發現的投資預計將推動分離技術領域的增長。 例如，2022 年 5 月，Cipla 宣佈在印度實現 COVID-19 PCR 試劑盒的商業化。 這種實時 RT-PCR 檢測試劑盒已在印度醫學研究委員會 (ICMR) 認可的中心進行了驗證。

分離技術，包括免疫沉澱、色譜技術和自動純化系統，可用於診斷和治療 COVID-19。 例如，根據 2021 年印度醫學研究雜誌，在印度北部的一家三級護理教學醫院進行了一項研究，以評估基於快速免疫測定的色譜測試在 COVID-19 診斷中的作用。 因此，基於免疫測定的快速色譜測試可以幫助快速檢測、隔離和治療 COVID-19 患者。

此外，與色譜技術相關的多項優勢使其在多個行業得到廣泛採用。 減少對大型色譜柱的需求等好處可提高生產過程的效率和生產率。 因此，每個部門越來越多地採用多種分離技術將增加對生命科學工具的需求並推動該部門的增長。

全球傳染病流行推動了生命科學工具的採用。 例如，根據 WHO 2021 Factsheet，2021 年將有 150 萬人死於結核病，全球估計有 1000 萬人患有結核病。 近年來，它一直在穩步下降。 但是，它仍然處於相當高的標準。

因此，上述因素預計將在預測期內推動細分市場的增長。

預計在預測期內北美將佔據重要的市場份額

推動北美市場增長的主要因素是基因組手術數量的增加、研發支出的增加、眾多大公司的存在、生物製藥公司的採用率增加、產品發布和技術進步等。

美國 COVID-19 的爆發導致診斷程序的增加，從而導致市場增長。 因此，事實證明，使用新技術進行的診斷有利於 COVID-19 的管理，從而推動生命科學設備市場的增長。

美國生物製藥行業正在顯著擴張，包括合成疫苗、納米抗體、rDNA、融合蛋白、免疫偶聯物、可溶性受體和免疫療法等新產品類型。 預計製藥和生物製藥行業增加對生命科學工具、研究和學術的研發投資將推動市場。

例如，根據美國研究和製藥製造商協會 (PhRMA) 的數據，美國生物製藥行業是新藥開發領域的世界領先者之一。 預計 2021 年生物製藥和製藥行業整體的研發 (R&D) 投資將達到約 911 億美元，而上一年約為 830 億美元。

此外，預計在預測期內，越來越多地採用新型藥物輸送系統和越來越多的傳染病患者將推動該地區的生命科學工具市場。

生命科學工具市場競爭對手分析

生命科學工具市場的競爭很低。 市場參與者正在採用產品批准和發布、收購、合作夥伴關係和協議等策略。 一些市場參與者包括 Becton、Dickinson and Company、Agilent Technologies、Illumina Inc.、Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd、Merck KGaA、GE Healthcare、Bruker QIAGEN。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 對生物製藥的需求不斷增長，對生命科學研究的資助不斷增加
    • 目標傳染病和遺傳病的發病率增加
  • 市場製約因素
    • 設備成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按類型
    • 設備
    • 消耗品
    • 服務
  • 按技術
    • PCR 和 qPCR
    • 桑格序列
    • 分離技術
    • 流式細胞術
    • 核酸微陣列
    • 質譜
    • 其他技術
  • 通過申請
    • 蛋白質組學技術
    • 基因組技術
    • 細胞生物學技術
    • 其他應用
  • 最終用戶
    • 研究所
    • 診斷研究所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Becton, Dickinson and Company
    • Agilent Technologies Inc.
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories Inc.
    • Merck KGaA
    • GE Healthcare
    • Bruker Corporation
    • Qiagen NV
    • Danaher Corporation
    • Abbott Laboratories Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 70668

The life science tools market is expected to record a CAGR of 7.5% during the forecast period.

Globally, the COVID-19 pandemic positively impacted the growth of the life science tools market with the rapid development of diagnostics, fast-tracked regulatory clearances, and increased distribution in various countries to help curb the spread of the virus. Various diagnostic procedures have always been essential in the detection of infectious diseases. Currently, several molecular assays and immunoassays are in place to detect COVID-19. However, in the aftermath of the pandemic, there has been increased research in the life sciences industry to prepare for any unexpected global pandemic burden. For instance, in September 2022, the WHO issued a guidance framework for the responsible use of life science tools. The Framework calls on leaders and other stakeholders to mitigate risks and safely govern dual-use research, which has a clear benefit but can be misused to harm humans, other animals, agriculture, and the environment. Hence, with the increasing focus on life science, the market studied is expected to grow significantly in the coming years.

Genomic technologies are increasingly being used globally to understand and contribute to developing new diagnostic tests or procedures for various diseases, boosting the market's growth. For instance, in September 2022, Becton, Dickinson, and Company (BD) and CerTest Biotec commercially launched their new molecular polymerase chain reaction (PCR) assay for the monkeypox virus for the US and global markets. The company has stated that this PCR assay will only be available for research purposes. With such new launches, the market is expected to witness strong growth over the forecast period.

Furthermore, technological advancements associated with sequencing technologies, chromatography methods, mass spectrometry, and other products led to the increasing adoption of these tools in hospitals, research labs, and diagnostic laboratories. According to the WHO 2021 Factsheet, 680,000 people died from HIV-related causes, and 1.5 million people acquired HIV. Thus, a high patient population will boost the demand for treatment and further increase the use of life sciences tools for identifying, diagnosing, and monitoring the progression of several infectious diseases.

Furthermore, the rising demand for diagnostic tests for a variety of infectious diseases will spur the development of life science tools for diagnosing the target population, propelling overall market growth over the forecast period.

Life Science Tools Market Trends

Life Science Tools in Separation Technologies is Estimated to Witness a Healthy Growth Rate Over the Forecast Period

The major factors driving the separation technologies segment include growing investments in pharmaceutical R&D and the increasing adoption of chromatography technologies by the life sciences industries.

Globally, the COVID-19 pandemic positively impacted the life science instruments market. The outbreak of COVID-19 resulted in an increased number of diseases, which led to a subsequent increase in research and development activities. Increasing investment in drug discovery is expected to fuel the growth of the separation technology segment. For example, in May 2022, Cipla announced the commercialization of its COVID-19 PCR kit in India. The real-time RT-PCR test kit has been validated by an Indian Council of Medical Research (ICMR)-approved center.

Separation technologies include immunoprecipitation, chromatographic techniques, automated purification systems, and others that aid in diagnosing and treating COVID-19. For example, according to the Indian Journal of Medical Research 2021, a study was conducted in a tertiary care teaching hospital in northern India to assess a rapid immunoassay-based chromatographic test in the diagnosis of COVID-19. The results of the study showed that immunoassay-based rapid chromatographic tests can help in the rapid detection, isolation, and treatment of patients with COVID-19.

In addition, this technology is widely adopted by several industries due to several advantages associated with chromatography technology. Benefits such as reducing the need for large columns increase the efficiency and productivity of the production process. Thus, increased adoption of multiple separation technologies across sectors would increase the demand for life science tools and drive segment growth.

The increasing prevalence of infectious diseases worldwide will encourage the adoption of life science tools. For example, according to the WHO 2021 Factsheet, 1.5 million people died of tuberculosis in 2021, and an estimated 10 million people contracted tuberculosis (TB) worldwide. It has been steadily declining in recent years. However, it is still at a much higher level.

Thus, the above-mentioned factors are expected to drive segment growth over the forecast period.

North America is Expected to Hold a Significant Market Share over the Forecast Period

The major factors driving market growth in North America include the rising number of genomic procedures, increasing research and development expenditure, the presence of a large number of major players, growing adoption among biopharmaceutical companies, product launches, and technological advancements.

With the outbreak of COVID-19 in the United States, there has been an increase in the number of diagnostic procedures, leading to market growth. Thus, diagnostic procedures with new technologies have proven beneficial in managing COVID-19 and are driving the growth of the life sciences instruments market.

The biopharmaceutical industry in the United States has expanded significantly to include new product types such as synthetic vaccines, nanoantibodies, rDNA, fusion proteins, immunoconjugates, soluble receptors, and immunotherapeutics. The pharmaceutical and biopharmaceutical industries' increased R&D investment in life science tools, research, and academics is expected to drive the market.

For example, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical industry is one of the world leaders in new drug development. The entire biopharmaceutical and pharmaceutical industry invested an estimated USD 91.1 billion in research and development (R&D) in 2021, compared to about USD 83 billion invested in research and development (R&D) in the previous year.​​

Furthermore, the increasing adoption of novel drug delivery systems and the rising prevalence of infectious disease cases are expected to fuel the life science tools market in the region over the forecast period.

Life Science Tools Market Competitor Analysis

The life science tools market is moderately competitive. The market players adopted strategies such as product approval and launches, acquisitions, partnerships, and agreements. Some of the market players include Becton, Dickinson and Company, Agilent Technologies, Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, GE Healthcare, and Bruker QIAGEN.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Demand for Biopharmaceuticals and Increasing Funding for Life Science Research
    • 4.2.2 Rising Incidence of Target Infectious Diseases and Genetic Disorders
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Instruments
    • 5.1.2 Consumables
    • 5.1.3 Services
  • 5.2 By Technology
    • 5.2.1 PCR and qPCR
    • 5.2.2 Sanger Sequencing
    • 5.2.3 Separation Technologies
    • 5.2.4 Flow Cytometry
    • 5.2.5 Nucleic Acid Microarray
    • 5.2.6 Mass Spectrometry
    • 5.2.7 Other Technologies
  • 5.3 By Application
    • 5.3.1 Proteomics Technology
    • 5.3.2 Genomic Technology
    • 5.3.3 Cell Biology Technology
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Research Laboratories
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Illumina Inc.
    • 6.1.4 Thermo Fisher Scientific Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Bio-Rad Laboratories Inc.
    • 6.1.7 Merck KGaA
    • 6.1.8 GE Healthcare
    • 6.1.9 Bruker Corporation
    • 6.1.10 Qiagen NV
    • 6.1.11 Danaher Corporation
    • 6.1.12 Abbott Laboratories Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS